TIVORBEX Drug Patent Profile
✉ Email this page to a colleague
When do Tivorbex patents expire, and when can generic versions of Tivorbex launch?
Tivorbex is a drug marketed by Genus and is included in one NDA. There are three patents protecting this drug.
This drug has thirty-seven patent family members in twenty-one countries.
The generic ingredient in TIVORBEX is indomethacin. There are fifteen drug master file entries for this compound. Thirty-two suppliers are listed for this compound. Additional details are available on the indomethacin profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Tivorbex
A generic version of TIVORBEX was approved as indomethacin by CHARTWELL MOLECULES on August 6th, 1984.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for TIVORBEX?
- What are the global sales for TIVORBEX?
- What is Average Wholesale Price for TIVORBEX?
Summary for TIVORBEX
International Patents: | 37 |
US Patents: | 3 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 164 |
Clinical Trials: | 2 |
Patent Applications: | 4,318 |
Drug Prices: | Drug price information for TIVORBEX |
What excipients (inactive ingredients) are in TIVORBEX? | TIVORBEX excipients list |
DailyMed Link: | TIVORBEX at DailyMed |
Recent Clinical Trials for TIVORBEX
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Sen-Jam Pharmaceutical | Phase 2 |
National University, Singapore | Phase 2 |
Iroko Pharmaceuticals, LLC | Phase 2 |
US Patents and Regulatory Information for TIVORBEX
TIVORBEX is protected by three US patents.
Patents protecting TIVORBEX
Formulation of indomethacin
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Formulation of indomethacin
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Formulation of indomethacin
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF PAIN
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Genus | TIVORBEX | indomethacin | CAPSULE;ORAL | 204768-001 | Feb 24, 2014 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Genus | TIVORBEX | indomethacin | CAPSULE;ORAL | 204768-002 | Feb 24, 2014 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Genus | TIVORBEX | indomethacin | CAPSULE;ORAL | 204768-001 | Feb 24, 2014 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for TIVORBEX
See the table below for patents covering TIVORBEX around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
China | 102438594 | A novel formulation of indomethacin | ⤷ Sign Up |
Colombia | 6470807 | UNA FORMULACION NOVEDOSA DE INDOMETACINA | ⤷ Sign Up |
South Korea | 20150030782 | A Novel formulation of indomethacin | ⤷ Sign Up |
>Country | >Patent Number | >Title | >Estimated Expiration |